A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
Financial Summary
| Share Statistics | SGIOY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16,012.9 | $419.8 | 84% |
|
| Shares Out (Mil) | 5.4 | 43.5 | 15% |
|
| Institutional Ownership | 50.0% | 80.9% | 30% |
|
| Float (Mil) | 824.1 | 46.7 | 89% |
|
| Beta | 0.10 | 0.71 | 9% |
|
| Avg Daily Volume (000s) | 54 | 281 | 30% |
|
| Price Change (52-week) |
12.8% | 53.5% | 62% |
|
| Growth | SGIOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.2% | 6.1% | 29% |
|
| Net Income (5yr) | 5.0% | (1.8%) | 47% |
|
| EPS (5yr) | 6.6% | 14.9% | 41 |
|
| Dividends (5yr) | 6.5% | 0.0% | 68% |
|
| Cash Flow (5yr) | 40.1% | (15.1%) | 90% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SGIOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,143 | $301 | 67% |
|
| Net Income (TTM) (Mil) | $1,290 | ($11) | 88% |
|
| EPS (TTM) | $1.516 | ($0.600) | 66% |
|
| Operating Cash Flow (TTM) (Mil) | $1,343 | ($6) | 84% |
|
| Net Cash Flow (TTM) (Mil) | $3,588 | $2 | 98% |
|
| Long-Term Debt (Q1) (Mil) | $119 | $6 | 45% |
|
| Enterprise Value (Q1) (Mil) | $18,402 | $446 | 83% |
|
| Valuation | SGIOY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.01 | na |
|
| P/E | na | 21.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SGIOY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.7% | 67.7% | 90% |
|
| Net Margin | 37.9% | 3.6% | 93% |
|
| ROA | 10.1% | (22.2%) | 87% |
|
| ROE | 13.8% | (21.5%) | 68% |
|
| Liabilities to Assets | 34.6% | 31.5% | 26% |
|
| F-Score | na | 3 | na |
|
Shionogi & Co., Ltd. did not pass any screens on 11/6/2026.
